Shots:

• The approval is based on data from the SYNAPSE study evaluating mepolizumab vs PBO in ~400 patients with CRSwNP who had a history of prior surgery & need further surgery due to severe symptoms & increased size of polyps
• The results showed a 57% reduction in the size of nasal polyps & nasal obstruction in patients who had surgery whereas the proportion of patients requiring systemic corticosteroid use through 52 wks. of the treatment period was lower who received the therapy
• Mepolizumab is the 1st anti-IL-5 biologic to be approved for CRSwNP & marks the 4th indication for eosinophil-driven diseases in the US

Ref: Businesswire | Image: GSK